Hemato-oncology
Pushing the boundaries of cancer treatment together!
With innovative and effective therapies, we want to enable people with blood cancer to live a better and longer life. We have been active in oncological research and drug development for more than ten years.
An overview of Hemato-oncology
AbbVie oncology is developing ground-breaking innovations in the field of hemato-oncology, thereby changing the lives of affected people around the world for the better. Here we have compiled comprehensive information for medical professionals as well as for patients and relatives. You will gain an insight into our commitment in the field of haematology, but above all practical information and services to support you in dealing with blood cancer.
Register to take advantage of our in-depth hemato-oncology content
Stay up-to-date with the latest hemato-oncology news and information plus access to our full range of hemato-oncology content; including educational resources, specialist articles, expert interviews, and more.
Already Registered? Log in now
A look into the future - our research into new blood cancer therapy options
Our pipeline for haemato-oncological diseases comprises a large number of new active ingredients that are currently being researched in more than 20 forms of cancer and tumour types as part of clinical studies. The indications include chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML) and multiple myeloma (MM).
The substances are in different study and approval phases.
Chronic lymphocytic leukaemia (CLL)
Chronic lymphocytic leukaemia (CLL) is the most common leukemic disease in Central Europe.1 In Germany, around 5,600 people are newly diagnosed with CLL every year.1
Since CLL is caused by the uncontrolled reproduction of functionless B-lymphocytes, a therapeutic approach aims to minimize the number of B-cells quickly and effectively. The innovative, targeted combination CLL therapy against BCL2 and CD20 as B-cell-specific targets has proven exactly that in clinical studies.
Due to the CLL treatment and patient benefits, CLL therapy was included in the guidelines of the German Society for Haematology and Medical Oncology (DGHO) in 2020.
Acute myeloid leukaemia (AML)
AML is the most common acute form of leukaemia in Germany.2 Only 3 to 4 AML cases per 100,000 population occur annually. However, the incidence increases with age to over 100 per 100,000 in those over 70 years of age.3 Most patients are between 66 and 71 years of age at the time of diagnosis of AML.2
AML is a genetically very heterogeneous disease in which immature myeloid progenitor cells multiply in an uncontrolled manner in the bone marrow. The prognosis depends heavily on individual factors such as the age and comorbidities of the sick person and the genetic properties of the AML cells.3
In the last few decades there has been intensive research in the field so that the AML treatment options have improved and new AML therapy options are available. Even if the prognosis is unfavourable, AML patients can gain valuable lifetime with the best possible quality of life with individual therapy.
Our oncology resources
CME Academy
Expand your knowledge of hemato-oncology and collect CME points in the process
Explore further
Our commitment to patients worldwide
Looking for more detailed patient information?
Sources
1. Onkopedia / DGHO guideline 2020; www.onkopedia.com, accessed on March 16, 2021
2. Nagel G, et al. Ann Hematol 2017; 96 (12): 1993-2003.
3. Röllig C, et al. onkopedia guidelines: Acute Myeloid Leukemia (AML). As of January 2021. https://www.onkopedia.com/de/onkopedia/guidelines/akute-myeloische-leukaemie-aml/@@guideline/html/index.html. Access date 06.04.2021.